The Meals and Drug Administration on Tuesday authorized Ozempic, the load loss drug made by Novo Nordisk A/S NVO, for the therapy of persistent kidney illness in sufferers who even have sort 2 diabetes.
The Particulars: Based on the Facilities for Illness Management and Prevention, greater than 35.5 million Individuals have persistent kidney illness, typically as a complication of sort 2 diabetes. The brand new FDA approval permits for additional growth of Ozempic’s use and potential protection by medical insurance plans.
Learn Subsequent: SoFi Inventory Falls On Mushy Steerage Regardless of ‘Robust Quarter’ With Report Member Development, Mortgage Originations: Analyst
The FDA approval “permits us to extra broadly handle circumstances inside cardiovascular-kidney-metabolic syndrome, which impacts hundreds of thousands of adults and will have severe penalties if left untreated,” Anna Windle, a senior vp at Novo Nordisk, mentioned in a press release Tuesday, per a Bloomberg report.
Ozempic and different diabetes medication often known as GLP-1s have turn out to be fashionable and in addition well-known for his or her excessive price.
Earlier in January, Novo Nordisk’s diabetes and weight reduction medication, Ozempic, Rybelsus, and Wegovy have been all added to the U.S. Division of Well being and Human Companies checklist of medicine lined beneath Medicare Half D which were chosen for mandated value negotiations as a way to cut back prescription drug prices.
The negotiations will happen in 2025, with the brand new costs slated to take impact in 2027.
NVO Worth Motion: Based on Benzinga Pro, Novo Nordisk shares ended Tuesday’s session down 2.65% at $85.19.
Learn Subsequent:
Picture: Shutterstock
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
